Hot Features
プレミアム
Kymera Therapeutics Inc (KYMR)
NASDAQ
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causin... Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients. 詳細を表示
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical...
KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the potential to address multiple immuno-inflammatory diseases KT-621 has demonstrated...
WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
KT-621 has demonstrated dupilumab-like activity and was well tolerated ina wide variety of preclinical models of TH2 diseases KT-621 is expected to start Phase 1 in October, with Phase 1 data in...
KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease KT-621 demonstrated strong degradation of STAT6 in human...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -9.56 | -18.3952280162 | 51.97 | 53.23 | 41.5 | 434963 | 46.43371805 | CS |
| 4 | -3.82 | -8.26303266277 | 46.23 | 53.23 | 41.5 | 410823 | 47.71078064 | CS |
| 12 | -7.17 | -14.4614764018 | 49.58 | 53.27 | 41.5 | 399056 | 47.47249282 | CS |
| 26 | 7.39 | 21.1022272987 | 35.02 | 53.27 | 29.24 | 500964 | 41.73212109 | CS |
| 52 | 22.96 | 118.046272494 | 19.45 | 53.27 | 18.89 | 623741 | 35.87326314 | CS |
| 156 | -20.14 | -32.1982414069 | 62.55 | 66.45 | 9.6 | 597745 | 30.1125585 | CS |
| 260 | 9.49 | 28.8274605103 | 32.92 | 91.92 | 9.6 | 513040 | 33.95611778 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
